November 12, 2018 14:59 - x 00, 0 - 00:00
Prof Andrea Manca, University of York, HARMONY Partner answers the following questions:
What information can EU funded Big Data projects like HARMONY contribute to these processes?
What are the main risks and benefits of adopting a precision, personalised and stratified medicine approach to inform treatment decisions in the European healthcare context?
Listen to his interview filmed during the 3rd HARMONY General Assembly, organized on 4 & 5 October 2018 at Hospital Universitario La Fe de la Comunidad Valenciana (HULAFE) in Valencia.
Big Data will have an impact on health care and in particular on the development of new drugs and therapies for patients. Blood cancers, or hematologic cancers such as leukemia, lymphoma, and myeloma, affect the production and function of blood cells, and account for about 40% of cancer cases in children and almost one third of the total cancer deaths. As many blood cancers are rare, and health care practice varies across EU, the current lack of data on relevant outcomes represents a challenge for clinicians, researchers, and other decision-makers like regulators and HTA bodies. This results in limitations for patient access to the best health care. The HARMONY Alliance aims to use ‘Big Data and Big Data analytics’ to deliver information that will help to improve the care of patients with these diseases.
HARMONY: Healthcare Alliance for Resourceful Medicines Offensive against Neoplasms in Hematology | The HARMONY Alliance is a European Network of Excellence for Big Data in Hematology, consisting of 53 Partners and 27 Associated members. Key stakeholders in the clinical, academic, patient advocacy, Health Technology Assessment, regulatory, economic, ethical, information and communications technology and pharmaceutical fields. HARMONY aims to unlock valuable knowledge on hematologic malignancies (HMs).
Focus: Acute Lymphoblastic Leukemia (ALL), Acute Myeloid Leukemia (AML), Chronic Lymphocytic Leukemia (CLL), Myelodysplastic Syndromes (MDS), Multiple myeloma (MM), Non-Hodgkin’s Lymphoma (NHL), and Pediatric Hematologic Malignancies.
The HARMONY Alliance is funded through the Innovative Medicines Initiative (IMI), Europe’s largest public-private initiative aiming to speed up the development of better and safer medicines for patients. HARMONY has received funding from IMI 2 Joint Undertaking and is listed under grant agreement No. 116026. This Joint Undertaking receives support from the European Union’s Horizon 2020 Research and Innovation Programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). IMI supports collaborative research projects and builds networks of industrial and academic experts in order to boost pharmaceutical innovation in Europe.
Receive the latest news. Click here to subscribe!